Evidence map›Paper›PMID 36158879›Full record

SynthesisBioMed research international2022

Potential of

Frank Eric Tatsing Foka, Nanabi Manamela, Steven Maluta Mufamadi, Hazel Tumelo Mufhandu

Abstract readSystematic Review
In one paragraph

Synthesis in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Frank Eric Tatsing FokaDepartment of Microbiology, Virology Lab, School of Biological Sciences, Faculty of Natural and Agricultural Sciences, North-West University, Mafikeng, Private Bag, X2046 Mmabatho, South Africa.ORCID https://orcid.org/0000-0001-6577-2827
Nanabi ManamelaDepartment of Microbiology, Virology Lab, School of Biological Sciences, Faculty of Natural and Agricultural Sciences, North-West University, Mafikeng, Private Bag, X2046 Mmabatho, South Africa.
Steven Maluta MufamadiFaculty of Health Sciences, Medical School, Nelson Mandela University, Missionvale Campus, P.O. Box 77000, Gqeberha 6031, South Africa.
Hazel Tumelo MufhanduDepartment of Microbiology, Virology Lab, School of Biological Sciences, Faculty of Natural and Agricultural Sciences, North-West University, Mafikeng, Private Bag, X2046 Mmabatho, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A rare type of pneumonia later on referred to as COVID-19 was reported in China in December 2019. Investigations revealed that this disease is caused by a coronavirus previously identified as SARS-CoV-2, and since then, it has become a global pandemic with new strains emerging rapidly as a result of genetic mutations. Various therapeutic options are being explored in order to eradicate this pandemic even though approved vaccine candidates are being currently rolled out globally. Most medicinal plant extracts have astonishing properties, and they can therefore be used in the biosynthesis of effective antiviral nanoparticles. In this systematic review, we aimed to highlight the specific attributes that make

Indexed as

AzadirachtaCOVID-19 Drug TreatmentNanoparticlesAntiviral AgentsSARS-CoV-2Antiviral Agents

Identifiers

PMID36158879
PMCPMC9499809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.